New form of Taxol approved.

Share this article:

Bristol-Myers Squibb's Taxol and Sanofi-Aventis' Taxotere have new competition with a new FDA approval. The new drug, Abraxane –which is manufactured by American Pharmaceutical Partners, was approved for women with advanced breast cancer who have not responded to chemotherapy Abraxane features an easier administration and avoids some side effects.
In its clinical trial involving 460 women, tumors shrank in 21.5 percent of those who got Abraxane compared with 11.1 percent of those who received Taxol. The company has not yet provided data on whether Abraxane extended the lives of those women.
The women getting Abraxane in the trial had fewer cases of severe neutropenia, a decrease in white blood cells that can leave a patient vulnerable to infections. Some side effects like nerve damage, severe pain in the muscles or joints, and vomiting were more common with Abraxane.
American Pharmaceutical Partners, based in Schaumburg, Ill., is a generic maker that, with Abraxane, is moving into branded drugs.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.